According to the previous study, FYN, LRSAM1, and SEMA6C serve as poor prognostic biomarkers in pancreatic cancer, whereas ERAP2, MET, IL20RB, and CXCL11 indicate improvements. This evidence concerns the gene MET and pancreatic neoplasm.